About Repare Therapeutics
Repare Therapeutics is a company based in Montreal (Canada) founded in 2016 by Daniel Durocher, Agnel sfeir, and Frank Sicheri was acquired by Alexis Bio in November 2025.. Repare Therapeutics has raised $165.5 million across 3 funding rounds from investors including TD Securities, Orbimed and Celgene. The company has 129 employees as of December 31, 2024. Repare Therapeutics offers products and services including RP-3467, RP-1664, Lunresertib, and Camonsertib. Repare Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Denali Therapeutics, C4 Therapeutics, Erasca and Revolution Medicines, among others.
- Headquarter Montreal, Canada
- Employees 129 as on 31 Dec, 2024
- Founders Daniel Durocher, Agnel sfeir, Frank Sicheri
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Repare Therapeutics Inc.
-
Annual Revenue
$53.48 M4.58as on Dec 31, 2024
-
Net Profit
$-84.69 M9.71as on Dec 31, 2024
-
EBITDA
$-89.29 M20.85as on Dec 31, 2024
-
Total Equity Funding
$165.5 M (USD)
in 3 rounds
-
Latest Funding Round
$15 M (USD), Series B
May 26, 2020
-
Investors
TD Securities
& 11 more
-
Employee Count
129
as on Dec 31, 2024
-
Acquired by
Alexis Bio
(Nov 14, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Repare Therapeutics
Repare Therapeutics is a publicly listed company on the NASDAQ with ticker symbol RPTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Repare Therapeutics
Repare Therapeutics offers a comprehensive portfolio of products and services, including RP-3467, RP-1664, Lunresertib, and Camonsertib. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Inhibitor targeting Polθ ATPase for cancer treatment
Inhibitor for PLK4 in oncology applications
PKMYTI inhibitor for cancer therapy development
ATR inhibitor used in precision oncology trials
Unlock access to complete
Unlock access to complete
Funding Insights of Repare Therapeutics
Repare Therapeutics has successfully raised a total of $165.5M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $15 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $15.0M
-
First Round
First Round
(22 Jun 2017)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2020 | Amount | Series B - Repare Therapeutics | Valuation | Bristol-Myers Squibb |
|
| Sep, 2019 | Amount | Series B - Repare Therapeutics | Valuation | Cowen | |
| Jun, 2017 | Amount | Series A - Repare Therapeutics | Valuation | MPM Capital , Versant Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Repare Therapeutics
Repare Therapeutics has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include TD Securities, Orbimed and Celgene. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
US private equity investments are managed by BVF Partners.
|
Founded Year | Domain | Location | |
|
Private equity fund focused on the biotechnology sector
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Repare Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Repare Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Repare Therapeutics Comparisons
Competitors of Repare Therapeutics
Repare Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Denali Therapeutics, C4 Therapeutics, Erasca and Revolution Medicines, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Repare Therapeutics
Frequently Asked Questions about Repare Therapeutics
When was Repare Therapeutics founded?
Repare Therapeutics was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Where is Repare Therapeutics located?
Repare Therapeutics is headquartered in Montreal, Canada. It is registered at Montreal, Quebec, Canada.
Is Repare Therapeutics a funded company?
Repare Therapeutics is a funded company, having raised a total of $165.5M across 3 funding rounds to date. The company's 1st funding round was a Series A of $68M, raised on Jun 22, 2017.
How many employees does Repare Therapeutics have?
As of Dec 31, 2024, the latest employee count at Repare Therapeutics is 129.
What is the annual revenue of Repare Therapeutics?
Annual revenue of Repare Therapeutics is $53.48M as on Dec 31, 2024.
What does Repare Therapeutics do?
Repare Therapeutics was founded in 2016 in Montreal, Canada, within the biotechnology sector. Targeted therapies addressing genetic alterations in selected tumors are developed using a genome-wide, CRISPR-enabled SNIPRx platform. This approach systematically identifies cancer treatments focused on genomic instability, such as DNA damage repair. The lead candidate, PolQ, inhibits Polθ to target tumors with mutations in homology-directed repair genes. Operations emphasize precision oncology for oncology applications.
Who are the top competitors of Repare Therapeutics?
Repare Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
What products or services does Repare Therapeutics offer?
Repare Therapeutics offers RP-3467, RP-1664, Lunresertib, and Camonsertib.
Is Repare Therapeutics publicly traded?
Yes, Repare Therapeutics is publicly traded on NASDAQ under the ticker symbol RPTX.
Who are Repare Therapeutics's investors?
Repare Therapeutics has 12 investors. Key investors include TD Securities, Orbimed, Celgene, BDC, and Bristol-Myers Squibb.
What is Repare Therapeutics's ticker symbol?
The ticker symbol of Repare Therapeutics is RPTX on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.